Related Experiment Video
Updated: Jun 30, 2026
06:19
Intracameral Injection in Rats with Low Risk of Adverse Effects
Published on: May 31, 2024
Subconjunctival bevacizumab for corneal neovascularization
Priyanka P Doctor1, Pooja V Bhat, C Stephen Foster
1Ocular Immunology and Uveitis Foundation, Massachusetts Eye Research and Surgery Institute, Harvard Medical School, Cambridge, MA 02142, USA.
Cornea
|September 25, 2008
Summary
Subconjunctival bevacizumab injections effectively reduced corneal neovascularization in patients with ocular surface inflammatory diseases. This treatment was well-tolerated and showed promise for improving vision and graft success.
Area of Science:
- Ophthalmology
- Corneal Disease Research
- Vascular Endothelial Growth Factor (VEGF) Inhibition
Background:
- Corneal neovascularization (CNV) is a significant cause of vision impairment, often associated with ocular surface inflammatory diseases.
- Current treatments for CNV have limitations, necessitating novel therapeutic strategies.
Observation:
- A retrospective case series evaluated 8 eyes of 7 patients with CNV.
- Patients received 1-3 injections of 2.5 mg subconjunctival bevacizumab.
- Clinical assessments monitored morphologic changes in corneal neovascularization.
Findings:
- Subconjunctival bevacizumab demonstrated a reduction in the neovascularized area in all treated eyes.
- The treatment was well-tolerated, with no significant corneal side effects observed.
- Bevacizumab, an anti-VEGF agent, appears effective in managing CNV.
Implications:
- Subconjunctival bevacizumab may offer a new therapeutic option for managing corneal neovascularization.
- This approach could potentially improve visual outcomes in patients with ocular surface inflammatory diseases.
- It may also enhance the success rates of corneal transplantation in affected individuals.
Related Concept Videos
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...